Comparing the current results to its competitors, Lexicon Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by -97.6 %, despite the revenue increase by the most of its competitors of 6.93 %, recorded in the same quarter.
Lexicon Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industries, which are highly competitive and rapidly evolving. It faces competition from other pharmaceutical and biotechnology companies, academic research institutions, clinical reference laboratories, and governmental agencies engaged in similar research and development activities. Many competitors possess greater research, development, commercialization capabilities, as well as more extensive financial, scientific, marketing, and human resources. These competitors may develop products earlier, secure regulatory approvals more quickly, create more effective products, or commercialize products more efficiently and profitably. Collaborators of the company also encounter similar competitive challenges.
July 15, 2024
Heart failure (HF) is a significant public health burden associated with high morbidity, mortality, and healthcare costs. The need for effective and cost-saving interventions is paramount, particularly in the context of alternative payment models (APMs) that prioritize value-based care. This article highlights the potential cost-savings and positive economic impact of INPEFA (sotagliflozin) for HF management, based on the new analysis of the pivotal Phase 3 SOLOIST-WHF trial.Innovative Treatment Option:INPEFA, a selective sodium-glucose co-transporter 1 and 2 (SGLT1/2) inhibitor, has demonstrated promising outcomes in the treatment of chronic HF. Its unique dual mechanism of action, targeting both glucose an...
March 12, 2024
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease Type 1 diabetes is a chronic condition characterized by the body s inability to produce sufficient insulin, leading to elevated blood glucose levels. Chronic kidney disease (CKD) is a common complication of diabetes, further exacerbating the challenges of managing blood sugar levels. Lexicon Pharmaceuticals, Inc. recently conducted a post hoc analysis of its inTandem3 Phase 3 trial to assess the effectiveness and safety of sotagliflozin treatment in patients with type 1 diabetes and CKD. The results of this analysis demonstrate promis...
March 11, 2024
aims to provide its readers with insightful articles surrounding advancements in the pharmaceutical industry. In this article, we will analyze two related publications concerning the resubmission of Sotagliflozin, a potential adjunct therapy for type 1 diabetes, and its impact on pharmaceutical company Lexicon.1. Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDAThe first article highlights Lexicon s decision to resubmit the New Drug Application (NDA) for Sotagliflozin, specifically targeting type 1 diabetes. This comes after receiving feedback from the U.S. Food and Drug Administration (FDA). The NDA resubmission indicates Lexicon s determination to address the ...
Publicly Traded Peers of Lexicon Pharmaceuticals Inc
Dianthus Therapeutics Inc Share Performance
+27.81%
This Quarter
Dianthus Therapeutics Inc
Profile
Dianthus Therapeutics Inc is a biotechnology company that focuses on developing novel genetic medicines for patients suffering from rare genetic diseases. Their business model revolves around leveraging cutting-edge gene therapy technologies to design and deliver innovative treatments. By partnering with academic institutions and utilizing a proprietary gene therapy platform, they aim to address unmet medical needs and provide potential new therapies for patients with genetic disorders.
Kalvista Pharmaceuticals Inc's business model primarily focuses on the development and commercialization of novel small molecule therapies for various diseases. They strive to discover and develop innovative treatments to address unmet medical needs, and aim to bring these therapies to market efficiently and effectively.
Kiniksa Pharmaceuticals International Plc Share Performance
+83.10%
This Year
Kiniksa Pharmaceuticals International Plc
Profile
Kiniksa Pharmaceuticals Ltd is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with debilitating diseases and unmet medical needs. Their business model revolves around identifying potential drug candidates, conducting rigorous research and development, and ultimately bringing these drugs to market to provide innovative treatment options. They generate revenue through the sale of their products and collaborations with other companies for the development and commercialization of their therapies.
Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
Sources:
Lexicon Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Lexicon Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
